Jason C Kovacic, MD, PhD
- PROFESSOR | Medicine, Cardiology
Research Topics:
Angiogenesis, Atherosclerosis, CardiovascularDr. Jason Kovacic graduated from The University of Melbourne Medical School in 1994, and then undertook residency and cardiology specialty training in interventional cardiology at St. Vincent’s Hospital in Sydney, Australia. Becoming a Fellow of The Royal Australasian College of Physicians in 2003, Jason then completed a PhD in cardiovascular medicine at the Victor Chang Cardiac Research Institute. In 2007 Jason became a Fellow of The American College of Cardiology and relocated to the USA, to the National Heart, Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH) in Bethesda, Maryland. At the NIH, Jason discovered critical new pathways that lead to blockage of the body’s blood vessels. Jason then moved to The Mount Sinai School of Medicine in New York. In parallel with his vital ongoing research to define new ways to prevent and treat vascular disease, Jason is a practicing interventional cardiologist, specializing in treating blockages of the heart arteries. He has authored numerous scientific and clinical papers on heart and vascular disease, and serves on a number of NIH committees. He has a particular interest in the use of stem cells to understand and treat heart disease. His combined understanding and ability to treat heart disease places him in a unique position to offer the most comprehensive patient care.
Clinical Focus
- Acute Coronary Syndrome
- Angiography
- Cardiac Catherization
- Cardiovascular Disease
- Congestive Heart Failure
- Coronary Angioplasty
- Coronary Artery Disease
- General Cardiology
- Heart Disease
- Hyperlipidemia/High Cholesterol
- Valvular Heart Disease
- Vasospastic Disease
Multi-Disciplinary Training Areas
Development, Regeneration, and Stem Cells [DRS], Genetics and Genomic Sciences [GGS]The Kovacic Laboratory seeks to increase our understanding of blockages of arteries of the heart and other vessels, and develop cell, stem cell, and gene-based approaches for the prevention and treatment of cardiovascular disease.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Kovacic did not report having any of the following types of financial relationships with industry during 2020 and/or 2021: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.